Science Translational Medicine Archives
Dec. 1, 2021—A study by Vanderbilt researchers sheds light on how current antidepressant drugs work and suggests a new drug target in depression.
Apr. 6, 2020—Researchers at Vanderbilt University Medical Center are playing a key role in the development of a potential new antiviral drug to treat COVID-19.
Mar. 12, 2020—Researchers from Vanderbilt-Ingram Cancer Center (VICC) discovered a role for MYCN in triple-negative breast cancer (TNBC), a particularly aggressive form of the disease, and identified a potential intervention for further clinical investigation.
Aug. 15, 2019—A study led by Anna Vilgelm, MD, PhD, and Ann Richmond, PhD, has identified a possible second-line treatment for melanoma patients.
Mar. 15, 2018—A new integrated imaging approach makes it possible to probe the molecules involved in invasive infections and can be broadly applied to any health or disease state.
Aug. 24, 2017—Vanderbilt University research-ers have relieved symptoms of Rett syndrome in a mouse model with a small molecule that works like the dimmer switch in an electrical circuit.
Aug. 9, 2017—Thanks to advances in treatment, the relative five-year survival rate from all combined subtypes of breast cancer now exceeds 90 percent and yet the disease remains the third leading cause of cancer deaths in the United States after lung and colorectal cancers.
Jun. 29, 2017—A new antiviral drug candidate inhibits a broad range of coronaviruses, including the SARS and MERS coronaviruses, a multi-institutional team of investigators reports this week in Science Translational Medicine.
May. 10, 2017—A study led by researchers at Vanderbilt University Medical Center (VUMC) and the University of Arizona College of Pharmacy has generated the first comprehensive catalog of diseases in a single population associated with variations in HLA genes that regulate the body's immune system.
Apr. 21, 2016—A targeted therapy for triple-negative breast cancer (TNBC), the most aggressive form of breast cancer, has shown potential promise in a recently published study. TNBC is the only type of breast cancer for which there are no currently approved targeted therapies.